{"id":"peg-ifn-ld-rbv-for-16-weeks","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"20-40","effect":"Anemia"},{"rate":"15-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"30-50","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon alpha (Peg-IFN) is a long-acting form of interferon that activates innate and adaptive immune responses against hepatitis C virus (HCV). Ribavirin (RBV) is a nucleoside analog that inhibits viral RNA synthesis and enhances interferon-induced immune responses. The combination therapy works synergistically to reduce HCV viral load and achieve sustained virologic response.","oneSentence":"Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress viral replication in hepatitis C infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:08.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT00532701","phase":"PHASE4","title":"Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-11","conditions":"Chronic Hepatitis C","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys plus Copegus"],"phase":"marketed","status":"active","brandName":"Peg-IFN + LD RBV for 16 weeks","genericName":"Peg-IFN + LD RBV for 16 weeks","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peg-IFN + LD RBV for 16 weeks is a treatment regimen studied for Chronic Hepatitis C. This regimen involves the combination of peginterferon alfa-2a and low-dose ribavirin, administered for 16 weeks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}